SCHEMBL2886201

SCHEMBL2886201

C[Si](C)(C)CCOCn1ccc2c([N+](=O)[O-])ccnc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.32
ALDH1A1 P00352 5/20 0.31
MAPT P10636 4/20 0.31
LMNA P02545 3/20 0.31
POLB P06746 2/20 0.31
NPC1 O15118 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
KDM4E B2RXH2 2/20 0.31
GAA P10253 1/20 0.31
BRD4 O60885 1/20 0.31
CTSB P07858 1/20 0.31
HSP90AA1 P07900 1/20 0.31
CHRM1 P11229 1/20 0.31
DRD2 P14416 1/20 0.31
ALOX12 P18054 1/20 0.31
ADRA2B P18089 1/20 0.31
ADRA2C P18825 1/20 0.31
CHRM3 P20309 1/20 0.31
HTR2C P28335 1/20 0.31
CTH P32929 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30417928 1.00 DGAT1 (0.32) DGAT1ALDH1A1MAPTLMNAPOLB
SCHEMBL25240510 0.81 KDM4E (0.31) ALDH1A1MAPTLMNAPOLBKDM4E
SCHEMBL2279186 0.81 DGAT1 (0.32) DGAT1ALDH1A1MAPTNPC1HTT
SCHEMBL29663899 0.81 DGAT1 (0.32) DGAT1ALDH1A1MAPTNPC1HTT
SCHEMBL2884986 0.80 DGAT1 (0.36) DGAT1ALDH1A1MAPTLMNANPC1
SCHEMBL20659493 0.80 MEN1 (0.38) ALDH1A1MAPTLMNAPOLBSMN1; SMN2
SCHEMBL29821497 0.80 MEN1 (0.38) ALDH1A1MAPTLMNAPOLBSMN1; SMN2
SCHEMBL20587908 0.80 S1PR4 (0.32)
SCHEMBL29822015 0.80 S1PR4 (0.32)
SCHEMBL101528 0.79 DGAT1 (0.40) DGAT1MAPTNPC1GAADUT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240190891-A1 PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-06-13 US disclosed
EP-4182323-B1 PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS CHIESI FARM SPA (IT) 2024-04-24 EP disclosed
CN-116075307-A Pyridooxazine amino derivatives as ALK5 inhibitors 奇斯药制品公司 2023-05-05 CN disclosed
US-7723347-B2 Substituted phenylamino-pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-25 US disclosed
US-7723347-B2 Substituted phenylamino-pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-25 US disclosed
EP-1742945-B1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES BAYER SCHERING PHARMA AG (DE) 2009-12-30 EP disclosed
US-20080269268-A1 Substituted Phenylamino-Pyrimidines BAYER HEALTHCARE AG (DE) 2008-10-30 US disclosed
US-20080269268-A1 Substituted Phenylamino-Pyrimidines BAYER HEALTHCARE AG (DE) 2008-10-30 US disclosed
EP-1742945-A1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES Bayer HealthCare AG (DE) 2007-01-17 EP disclosed
WO-2005108397-A1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES BAYER HEALTHCARE AG (DE) 2005-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269268-A1 Substituted Phenylamino-Pyrimidines TYMP, DPYD, HPRT1 DGAT1 4366/4885ALDH1A1 598/4885MAPT 3319/4885
US-20240190891-A1 PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS TGFBR1, ACVR1, ALK DGAT1 4181/4885ALDH1A1 577/4885MAPT 2720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.